Skip to main content

Advertisement

Table 2 Indices of beta-cell function, insulin sensitivity and clearance

From: Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

Variable (unit) Baseline n Placebo n p Liraglutide n p Difference n p
BTotal 2.72 (2.00; 3.24) 29 − 0.14 (− 0.59; 0.37) 28 0.16 0.2 (− 0.54; 0.79) 25 0.42 0.25 (− 0.35; 0.93) 24 0.24
DI 8.23 (5.87; 12.93) 28 1.77 (− 1.83; 4.91) 27 0.06 6.0 (2.78; 9.23) 25 < .0001 3.35 (− 0.51; 9.29) 24 0.0005
IDRbasal (pmol/kg/min) 3.2 (2.18; 4.37) 29 − 0.28 (− 0.92; 0.25) 28 0.1 − 0.16 (− 1.13; 0.27) 26 0.22 0.13 (− 1.01; 0.84) 25 0.84
ISIComposite (L2/mg/microU) 3.15 (2.03; 4.5) 30 0.73 (− 0.05; 2.31) 29 0.0005 1.68 (0.57; 3.34) 27 < .0001 0.26 (− 0.81; 2.26) 27 0.14
HOMA-IR 4.43 (2.75; 6.93) 30 − 0.74 (− 2.06; − 0.12) 28 0.007 − 1.32 (− 2.88; − 0.25) 26 0.0003 − 0.39 (− 1.98; 0.79) 26 0.43
MCRikg (ml/kg/min) 29.35 (23.47; 35.07) 29 1.65 (− 0.99; 4.38) 28 0.08 3.56 (0.29; 7.02) 27 0.005 2.92 (− 2.47; 6.55) 26 0.06
MCRitotal (L/min) 2.54 (2.17; 3.33) 29 0.11 (− 0.10; 0.36) 28 0.15 0.27 (0.02; 0.37) 26 0.02 0.25 (− 0.24; 0.49) 25 0.13
HEXi 0.293 (0.208; 0.359) 29 0.024 (− 0.089; 0.083) 28 0.69 0.017 (− 0.073; 0.106) 26 0.72 0.058 (− 0.137; 0.146) 25 0.97
  1. Units are mmol/l × 120min except for insulin secretion rate (ISR) measured i pmol/kg. Data reported as median (IQR)